No Data
No Data
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
Morgan Stanley Downgrades BioAge Labs to Underweight From Overweight, Slashes Price Target to $5 From $40
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman
Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday
Express News | Bioage Labs Falls 76.9% After Jefferies Cuts PT on Co
Traders Eye Key Inflation Report as US Equity Futures Waver Pre-Bell
Strik57 : I believe way oversold,clinical trails are testing new drugs n if issue stop trails.more to them then just one they stop because safety issues so added some to my portfolio again today
Green-Day OP Strik57 : Nice! I also like that this company has integrity!
TheLongKhan : guess we're in it for the long haul
Green-Day OP TheLongKhan : Maybe don’t have to wait very long
103753999 : Time to buy
View more comments...